Gene Solutions, a Singapore-headquartered biotechnology company, has secured $100,000,000 in a recent funding round from investors. This substantial capital infusion will support the company's mission to deliver accessible genetic testing services across its expansive network.
Established in 2017, Gene Solutions offers a comprehensive genetic testing portfolio utilizing Next-Generation Sequencing (NGS) and Artificial Intelligence algorithms. Its services encompass cell-free DNA non-invasive prenatal testing (NIPT), circulating tumor DNA (ctDNA) cancer screening, genomic profiling, and treatment monitoring. The company operates a network of nine NGS laboratories, including two central CAP-accredited facilities in Singapore and Vietnam, and has provided over two million tests to patients.
The newly raised capital is earmarked for accelerating Gene Solutions' research and development initiatives, enhancing its laboratory infrastructure, and broadening its market reach. This funding round signifies a strong vote of confidence in the company's innovative genetic testing solutions and its proven track record in the biotechnology sector. The capital will also enable Gene Solutions to further its commitment to making advanced diagnostics available to more than 4,500 hospitals and clinics across Singapore, Vietnam, Thailand, Indonesia, Malaysia, the Philippines, Hong Kong SAR, Taiwan, India, Turkey, and USA.
With this significant investment, Gene Solutions is well-positioned to continue its trajectory of growth and innovation. The company aims to further democratize access to advanced genetic testing services, ultimately improving patient outcomes and solidifying its leadership in precision medicine across its diverse operational regions.
